Plasma lysophosphatidylcholine levels: Potential biomarkers for colorectal cancer

Journal of Clinical Oncology

Volumn 25, Issue 19, 2007, Pages 2696-2701

  Zhao, Zhenwen ^a   Xiao, Yijin ^a   Elson, Paul ^a   Tan, Haiyan ^a   Plummer, Sarah J ^a   Berk, Michael ^a   Aung, Phyu P ^a   Lavery, Ian C ^a   Achkar, Jean P ^a   Li, Li ^a   Casey, Graham ^a   Xu, Yan ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LYSOPHOSPHATIDYLCHOLINE; TUMOR MARKER;

ADULT; ARTICLE; BLOOD ANALYSIS; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; AGED; BLOOD; COLORECTAL TUMOR; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; ROC CURVE;

ADULT; AGED; CHROMATOGRAPHY, LIQUID; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LYSOPHOSPHATIDYLCHOLINES; MALE; MASS SPECTROMETRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 34447545773     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.5571     Document Type: Article

References (54)

1. Winawer S, Fletcher R, Rex D, et al: Colorectal cancer screening and surveillance: Clinical guidelines and rationale - Update based on new evidence. Gastroenterology 124:544-560, 2003
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006
3. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005
4. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54:8-29, 2004
5. Vernon SW: Participation in colorectal cancer screening: A review. J Natl Cancer Inst 89:1406-1422, 1997
6. Shelton BK: Introduction to colorectal cancer. Semin Oncol Nurs 18:2-12, 2002
7. Srivastava S, Verma M, Henson DE: Biomarkers for early detection of colon cancer. Clin Cancer Res 7:1118-1126, 2001
8. Molnar B, Sipos F, Galamb O, et al: Molecular detection of circulating cancer cells: Role in diagnosis, prognosis and follow-up of colon cancer patients. Dig Dis 21:320-325, 2003
9. Muller O: Identification of colon cancer patients by molecular diagnosis. Dig Dis 21:315-319, 2003
10. Doolittle BR, Emanuel J, Tuttle C, et al: Detection of the mutated K-Ras biomarker in colorectal carcinoma. Exp Mol Pathol 70:289-301, 2001
11. Dong SM, Traverso G, Johnson C, et al: Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 93:858-865, 2001
12. Calistri D, Rengucci C, Bocchini R, et al: Fecal multiple molecular tests to detect colorectal cancer in stool. Clin Gastroenterol Hepatol 1:377-383, 2003
13. Berger BM, Vucson BM, Diteberg JS: Gene mutations in advanced colonic polyps: Potential marker selection for stool-based mutated human DNA assays for colon cancer screening. Clin Colorectal Cancer 3:180-185, 2003
14. Berger BM, Robison L, Glickman J: Colon cancer-associated DNA mutations: Marker selection for the detection of proximal colon cancer. Diagn Mol Pathol 12:187-192, 2003
15. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 351:2704-2714, 2004
16. Chen WD, Han ZJ, Skoletsky J, et al: Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 97:1124-1132, 2005
17. Moolenaar WH, van Meeteren LA, Giepmans BN: The ins and outs of lysophosphatidic acid signaling. Bioessays 26:870-881, 2004
18. Xu Y, Xiao YJ, Zhu K, et al: Unfolding the pathophysiological role of bioactive lysophospholipids. Curr Drug Targets Immune Endocr Metabol Disord 3:23-32, 2003
19. Chun J, Rosen H: Lysophospholipid receptors as potential drug targets in tissue transplantation and autoimmune diseases. Curr Pharm Des 12:161-171, 2006
20. Moolenaar WH: Development of our current understanding of bioactive lysophospholipids. Ann N Y Acad Sci 905:1-10, 2000
21. Sengupta S, Wang Z, Tipps R, et al: Biology of LPA in health and disease. Semin Cell Dev Biol 15:503-512, 2004
22. Mills GB, Moolenaar WH: The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3:582-591, 2003
23. Sengupta S, Kim KS, Berk MP, et al: Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. Oncogene 26:2894-901, 2007
24. Ren J, Xiao YJ, Singh LS, et al: Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 66:3006-3014, 2006
25. Kim KS, Sengupta S, Berk M, et al: Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res 66:7983-7990, 2006
26. Baudhuin LM, Jiang Y, Zaslavsky A, et al: S1P3-mediated Akt activation and cross-talk with platelet-derived growth factor receptor (PDGFR). Faseb J 18:341-343, 2004
27. Sengupta S, Xiao YJ, Xu Y: A novel laminin-induced LPA autocrine loop in the migration of ovarian cancer cells. Faseb J 17:1570-1572, 2003
28. Xu Y, Shen Z, Wiper DW, et al: Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280:719-723, 1998
29. Sutphen R, Xu Y, Wilbanks GD, et al: Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 13:1185-1191, 2004
30. Yoon HR, Kim H, Cho SH: Quantitative analysis of acy-lysophosphatidic acid in plasma using negative ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 788:85-92, 2003
31. Sedlakova I, Vavrova J, Tosner J, et al: Lysophosphatidic acid in ovarian cancer patients [Czech]. Ceska Gynekol 71:312-317, 2006
32. Baker DL, Morrison P, Miller B, et al: Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA 287:3081-3082, 2002
33. Xiao YJ, Schwartz B, Washington M, et al: Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: Comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem 290:302-313, 2001
34. Xiao Y, Chen Y, Kennedy AW, et al: Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann N Y Acad Sci 905:242-259, 2000
35. Ahmed FE: Colon cancer: Prevalence, screening, gene expression and mutation, and risk factors and assessment. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 21:65-131, 2003
36. Reference deleted
37. Reference deleted
38. Okita M, Gaudette DC, Mills GB, et al: Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine (lysoPC) in ovarian cancer patients. Int J Cancer 71:31-34, 1997
39. Sasagawa T, Okita M, Murakami J, et al: Abnormal serum lysophospholipids in multiple myeloma patients. Lipids 34:17-21, 1999
40. Moolenaar WH: Lysophospholipids in the limelight: Autotaxin takes center stage. J Cell Biol 158:197-199, 2002
41. Umezu-Goto M, Kishi Y, Taira A, et al: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158:227-233, 2002
42. Tokumura A, Majima E, Kariya Y, et al: Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 277:39436-39442, 2002
43. Clair T, Aoki J, Koh E, et al: Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res 63:5446-5453, 2003
44. Milstien S, Spiegel S: Targeting sphingosine-1-phosphate: A novel avenue for cancer therapeutics. Cancer Cell 9:148-150, 2006
45. Kishi Y, Okudaira S, Tanaka M, et al: Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 281:17492-17500, 2006
46. Zhang G, Zhao Z, Xu S, et al: Expression of autotaxin mRNA in human hepatocellular carcinoma. Chin Med J (Engl) 112:330-332, 1999
47. Yang Y, Mou L, Liu N, et al: Autotaxin expression in non-small-cell lung cancer. Am J Respir Cell Mol Biol 21:216-222, 1999
48. Yang SY, Lee J, Park CG, et al: Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin Exp Metastasis 19:603-608, 2002
49. Quinones LG, Garcia-Castro I: Characterization of human melanoma cell lines according to their migratory properties in vitro. In Vitro Cell Dev Biol Anim 40:35-42, 2004
50. Nam SW, Clair T, Campo CK, et al: Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene 19:241-247, 2000
51. Kehlen A, Englert N, Seifert A, et al: Expression, regulation and function of autotaxin in thyroid carcinomas. Int J Cancer 109:833-838, 2004
52. Hoelzinger DB, Mariani L, Weis J, et al: Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 7:7-16, 2005
53. Petricoin EF, Belluco C, Araujo RP, et al: The blood peptidome: A higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 6:961-967, 2006
54. Ciordia S, de Los Rios V, Albar JP: Contributions of advanced proteomics technologies to cancer diagnosis. Clin Transl Oncol 8:566-580, 2006